<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001077</url>
  </required_header>
  <id_info>
    <org_study_id>CPCRA 038</org_study_id>
    <secondary_id>11588</secondary_id>
    <nct_id>NCT00001077</nct_id>
  </id_info>
  <brief_title>A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements</brief_title>
  <official_title>An Open-Label, Randomized, Three-Arm, Comparative Trial of a Caloric Supplement With Peptides and Medium-Chain Triglycerides Versus a Caloric Supplement With Whole Protein and Long-Chain Triglycerides Versus No Caloric Supplement for the Prevention of Weight Loss in Individuals With AIDS Who Take a Daily Multivitamin and Mineral Supplement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To compare a caloric supplement containing peptides and medium-chain triglycerides, a caloric
      supplement containing whole protein and long-chain triglycerides, and no caloric supplement
      for the prevention of weight loss in individuals with AIDS who take a daily multivitamin and
      mineral supplement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to one of 3 study arms:

      Arm 1 - Peptamen drinks + multivitamin and mineral supplement, taken in addition to regular
      diet for 4 months Arm 2 - NuBasics drinks or equivalent amounts of NuBasics soups or bars +
      multivitamin and mineral supplement, taken in addition to regular diet for 4 months Arm 3 -
      Multivitamin and mineral supplement, taken in addition to regular diet for 4 months.

      At months 0, 2, and 4, patients will be assessed for weight, body cell mass, patient-reported
      physical activity level, and dietary intake (by 24-hour dietary recall). At months 2 and 4,
      they will also be assessed for compliance with study regimen. Patients who complete their 4
      month follow up visit will be provided with a 30 day supply of the caloric supplement of
      their choice (Peptamen or NuBasics) and a 30 day supply of the study multivitamin supplement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1996</start_date>
  <completion_date type="Actual">April 1998</completion_date>
  <primary_completion_date type="Actual">April 1998</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">536</enrollment>
  <condition>HIV Infections</condition>
  <condition>HIV Wasting Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Participants will receive peptamen drinks and multivitamin and mineral supplements, taken in addition to a regular diet for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Participants will receive NuBasics drinks or equivalent amounts of NuBasics soups or bars and daily multivitamin and mineral supplements, taken in addition to a regular diet for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Participants will receive multivitamin and mineral supplements, taken in addition to a regular diet for 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multivitamin and mineral supplements</intervention_name>
    <description>Oral tablets taken daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Peptamen</intervention_name>
    <description>Solution received daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>NuBasics</intervention_name>
    <description>Solution or dietary bar received daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood collection
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected participants who take a daily multivitamin and mineral supplement
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  HIV infection.

          -  Stable weight.

          -  CD4+ cell count &lt;200 cells/mm3.

          -  Life expectancy of at least 6 months.

          -  Parent or legal guardian to sign written, informed consent for patients &lt; 18 years
             old.

        Exclusion Criteria

        Co-existing Condition:

        Patients with any of the following symptoms or conditions are excluded:

          -  Active opportunistic infection, requiring acute treatment.

          -  Malignancy (other than stable cutaneous Kaposi's sarcoma that does not require
             systemic chemotherapy).

          -  Diabetes mellitus or other conditions requiring special dietary restrictions.

          -  Body mass index (BMI) &gt;= 29.0 kg/m2.

          -  Disorders or conditions that, in the treating clinician's opinion, may prevent
             adequate compliance with protocol requirements.

        Concurrent Medication:

        Excluded:

          -  Growth hormone.

          -  Megestrol acetate (Megace).

          -  Cyproheptadine (Periactin).

          -  Dronabinol (Marinol).

          -  Thalidomide.

          -  Anabolic steroids (e.g., nandrolone decanoate)(Deca-durabolin).

          -  Pharmacologic-dose corticosteroids (e.g., &gt; 15 mg/day prednisone equivalent)

        NOTE:

          -  Men requiring testosterone replacement therapy for documented hypogonadism may be
             enrolled.

          -  Caloric nutritional supplements deemed by the clinician to promote weight gain or
             maintenance.

        Patients with the following prior condition are excluded:

          -  History of phenylketonuria.

        Prior Medication:

        Excluded within the past 2 weeks:

          -  Use of caloric nutritional supplements for more than 5 days deemed by the clinician to
             promote weight gain or maintenance.

        Excluded within the past 30 days:

          -  Growth hormone.

          -  Megestrol acetate (Megace).

          -  Cyproheptadine (Periactin).

          -  Dronabinol (Marinol).

          -  Thalidomide.

          -  Anabolic steroids (e.g., nandrolone decanoate)(Deca-durabolin)

          -  Pharmacologic-dose corticosteroids (e.g., &gt; 15 mg/day prednisone equivalent).

        NOTE:

          -  Men requiring testosterone replacement therapy for documented hypogonadism may be
             enrolled.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilbert CL</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Wheeler D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Community Consortium / UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver CPCRA / Denver Public Hlth</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Reg AIDS Prog / Dept of Infect Dis</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - Saint Luke's Med Ctr</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Alliance - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Comm AIDS Rsch Prog / Tulane Univ Med</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baltimore Trials</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State Univ / WSU / DMC HIV / AIDS Program</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hosp</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern New Jersey AIDS Cln Trials / Dept of Med</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Jersey Community Research Initiative</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Partners in Research - New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Partners Research</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem AIDS Treatment Group / Harlem Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland Veterans Adm Med Ctr / Rsch &amp; Education Grp</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia FIGHT</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gibert CL, Muurahainen N, Collins G, Williams B, Raghavan S, Bartsch G, Wheeler D. Body composition in HIV-infected men and women in 1996-1997 (CPCRA 038). Int Conf AIDS. 1998;12:554 (abstract no 32169)</citation>
  </reference>
  <reference>
    <citation>Williams SB, Collins G, Muurahainen N, Bartsch G, Gibert C, Raghavan SS, Wheeler D. Protein intake is associated with body cell mass in weight-stable HIV+ men with CD4 &lt; 200 cells/mm3: CPCRA 038. Int Conf AIDS. 1998;12:841-2 (abstract no 42339)</citation>
  </reference>
  <reference>
    <citation>Muurahainen N, Mulligan K. Clinical trials update in human immunodeficiency virus wasting. Semin Oncol. 1998 Apr;25(2 Suppl 6):104-11. Review.</citation>
    <PMID>9625392</PMID>
  </reference>
  <reference>
    <citation>Muurahainen N, Collins G, Wheeler D, Mateo N, Madans M, Bartsch G, Gilbert C. Body cell mass (BCM) in HIV-infected (HIV+) males in the community programs for clinical research on AIDS (CPCRA) in 1996-1997. Int Conf AIDS. 1998;12:840 (abstract no 42333)</citation>
  </reference>
  <reference>
    <citation>Gibert CL, Wheeler DA, Collins G, Madans M, Muurahainen N, Raghavan SS, Bartsch G. Randomized, controlled trial of caloric supplements in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr. 1999 Nov 1;22(3):253-9.</citation>
    <PMID>10770345</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>September 28, 2013</last_update_submitted>
  <last_update_submitted_qc>September 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Weight Loss</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Nutritional Support</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>HIV Wasting Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

